Straits Times Index
3,246.52 -13.51 (-0.41%) Nikkei
26,717.34 +547.04 (+2.09%) Hang Seng
23,550.08 -256.92 (-1.08%) FTSE 100
7,514.46 -39.85 (-0.53%) BTC-USD
36,615.58 +557.48 (+1.55%) CMC Crypto 200
829.29 +9.79 (+1.19%)
Vertex Pharmaceuticals Incorporated (VRTX)
After hours:
| Previous close | 226.58 |
| Open | 228.99 |
| Bid | 0.00 x 1100 |
| Ask | 0.00 x 1200 |
| Day's range | 227.00 - 233.69 |
| 52-week range | 176.36 - 234.58 |
| Volume | |
| Avg. volume | 1,951,247 |
| Market cap | 58.025B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | 25.33 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
BOSTON, January 26, 2022--Vertex Reports Fourth Quarter 2021 and Full Year Financial Results
- Business Wire
Vertex to Announce Fourth Quarter 2021 Financial Results on January 26
BOSTON --, January 18, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2021 financial results on Wednesday, January 26, 2022 after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. To access the call, please dial (866) 501-1537 (U.S.) or +1 (720) 545-0001 (International).
- Business Wire
European Commission Approves KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in Combination With Ivacaftor to Treat Children With Cystic Fibrosis Ages 6 to 11 Years
LONDON, January 11, 2022--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label extension of KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients ages 6 through 11 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
